![Western Blot: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY TNFRSF8.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Western-Blot-NBP2-46157-img0021.jpg "Western Blot: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY TNFRSF8.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, Flow, IHC |
| Clone | OTI1C6 |
| Clonality | Monoclonal |
| Host | Mouse |
| Conjugate | Unconjugated |
| Concentration | 1 mg/ml |
| Immunogen | Human recombinant protein fragment corresponding to amino acids 19-379 of human TNFRSF8 (NP_001234) produced in E.coli. |
| Isotype | IgG1 |
| Clonality | Monoclonal |
| Host | Mouse |
| Gene | TNFRSF8 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Theoretical MW | 61.9 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Reviewed Applications |
|
| Storage | Store at -20C. Avoid freeze-thaw cycles. |
| Buffer | PBS (pH 7.3), 1.0% BSA and 50% Glycerol |
| Preservative | 0.02% Sodium Azide |
| Concentration | 1 mg/ml |
| Purity | Immunogen affinity purified |
| Images | Ratings | Applications | Species | Date | Details | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enlarge |
reviewed by:
Verified Customer |
IHC-Fr | Human | 08/29/2017 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for CD30/TNFRSF8 Antibody (NBP2-46157)Find related products by research area.
|
|
Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | TNFRSF8 |
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human endometrium tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0020.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human endometrium tissue.")
![Flow Cytometry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - (Blue).(1:100)](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Flow-Cytometry-NBP2-46157-img0022.jpg "Flow Cytometry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - (Blue).(1:100)")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lymphoma tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0001.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lymphoma tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human kidney tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0002.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human kidney tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lung tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0003.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lung tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human ovary tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0004.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human ovary tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human bladder tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0005.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human bladder tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human prostate tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0006.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human prostate tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human bladder tissue..](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0007.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human bladder tissue..")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human Kidney tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0008.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human Kidney tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human breast tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0009.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human breast tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human liver tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0010.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human liver tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human Ovary tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0011.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human Ovary tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human pancreas tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0012.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human pancreas tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human thyroid tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0013.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human thyroid tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human colon tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0014.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human colon tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lymph node tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0015.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human lymph node tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human endometrium tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0016.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human endometrium tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human colon tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0017.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Adenocarcinoma of Human colon tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human thyroid tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0018.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Human thyroid tissue.")
![Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human prostate tissue.](http://images.novusbio.com/fullsize/CD30-TNFRSF8-Antibody-1C6-Immunohistochemistry-NBP2-46157-img0019.jpg "Immunohistochemistry: CD30/TNFRSF8 Antibody (1C6) [NBP2-46157] - Analysis of Carcinoma of Human prostate tissue.")
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Immunohistochemistry CD45 Antibody [Unconjugated]](https://images.novusbio.com/images2/CD45_AF114_Immunohistochemistry_23525.jpg)
![Immunocytochemistry CD45 Antibody [Unconjugated]](https://images.novusbio.com/images2/af114_mouse-cd45-affinity-purified-polyclonal-ab-immunocytochemistry-6122021145449.jpg)
![Immunocytochemistry/ Immunofluorescence CD45 Antibody [Unconjugated]](https://images.novusbio.com/images/af114_mouse-cd45-affinity-purified-polyclonal-ab-41202410331954.jpg)
![Bioactivity IL-4 [Unconjugated]](https://images.novusbio.com/images/protein/6507-ilcf_recombinant-human-il-4-cho-expressed-protein-cf-bioactivity-272020133214.jpg)
![Bioactivity IL-2 [Unconjugated]](https://images.novusbio.com/images/202-il_recombinant-human-il-2-protein-bioactivity-174202314946.jpg)
![Immunohistochemistry CD30 Ligand/TNFSF8 Antibody [Unconjugated]](https://images.novusbio.com/images2/CD30_Ligand_AF1028_Immunohistochemistry_20252.jpg)
![Immunohistochemistry CD30 Ligand/TNFSF8 Antibody [Unconjugated]](https://images.novusbio.com/images2/CD30_Ligand_AF1028_Immunohistochemistry_20253.jpg)
![Flow Cytometry CD30 Ligand/TNFSF8 Antibody [Unconjugated]](https://images.novusbio.com/images2/af1028_human-cd30-ligand-tnfsf8-affinity-purified-polyclonal-ab-flow-cytometry-286202212274.jpg)
![N/A CD25/IL-2R alpha [HRP]](https://images.novusbio.com/images2/IL-2_R_alpha_DR2A00_ELISA_167.jpg)
![N/A CD25/IL-2R alpha [HRP]](https://images.novusbio.com/images2/DATA_CD25_DR2A00_ELISA_800.jpg)
![Western Blot ALK/CD246 Antibody [Unconjugated]](https://images.novusbio.com/images2/ALK_AF4210_Western_Blot_12746.jpg)
![Immunohistochemistry ALK/CD246 Antibody [Unconjugated]](https://images.novusbio.com/images2/12780.jpg)
![Simple Western ALK/CD246 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af4210_human-alk-cd246-affinity-purified-pab-simple-western-296202315837.jpg)
![Bioactivity IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFNgamma_285IF_2848.jpg)
![SDS-PAGE IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFN-gamma_285-IF_230.jpg)
![SEC-MALS IFN-gamma [Unconjugated]](https://images.novusbio.com/images/285-if_recombinant-human-ifn-gamma-protein-sec-mals-1520239228..jpg)
![SDS-Page: Mouse IgG1 Isotype Control (MG1) [NBP1-97005] - Lane 1: , Non-reduced. M: Opal Pre-stained Ladder. Lane 2: , Reduced. Load: 1.0 ug per lane. Predicted/Observed: 120 kDa Non-reduced, 55 and 25 Reduced.](https://images.novusbio.com/images/Mouse-IgG1-Isotype-Control-MG1-SDS-Page-NBP1-97005-img0002.jpg "SDS-Page: Mouse IgG1 Isotype Control (MG1) [NBP1-97005] - Lane 1: , Non-reduced. M: Opal Pre-stained Ladder. Lane 2: , Reduced. Load: 1.0 ug per lane. Predicted/Observed: 120 kDa Non-reduced, 55 and 25 Reduced.")
